Navigation Links
Bayer HealthCare's MEDRAD Interventional Business Announces Five-Year Data of Cotavance® Drug Eluting Balloon with Paccocath® Technology to be Presented at 2011 TCT
Date:11/3/2011

WARRENDALE, Pa., Nov. 3, 2011 /PRNewswire/ -- MEDRAD Interventional, a business of Bayer HealthCare, today announced that five-year data from the THUNDER trial will be presented at the 2011 Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in San Francisco. The data will focus on five-year rates of target lesion revascularization comparing the Cotavance® drug eluting balloon (DEB) catheter with Paccocath® Technology to standard balloon angioplasty (POBA) in popliteal arteries of patients with peripheral arterial disease (PAD). Presented by Prof. Dr. med. Thomas Zeller of Herz-Zentrum, Bad Krozingen, Germany, during the TCT-sponsored symposium, "Drug-Coated Balloons: Clinical Data and Applications," at 2 p.m. PST Nov. 10, the results will continue to build on the long-term clinical experience with the Paccocath® technology, which is available in Europe, but not yet approved in the U.S.

"The only published positive long-term clinical results to date with drug-eluting balloons have used MEDRAD's Paccocath technology, and these new data will now provide additional information out to five years, the longest time studied among DEBs," said Jack Darby, Senior Vice President of MEDRAD Interventional. "We remain committed to further elucidating long-term clinical outcomes with the Cotavance paclitaxel eluting balloon catheter compared to or in combination with other interventional therapies through our large clinical studies and registry program. Collectively, this will include more than 1,700 patients and approximately 200 centers around the world."

MEDRAD Interventional will have an extensive presence at the 2011 TCT conference. In addition to the presentation of new five-year data, MEDRAD is supporting two symposia, Management of Thrombus in STEMI Interventions: Discussion and Debate on the Role of AngioJet Thrombectomy and Manual Aspiration (Wednesday, Nov.
'/>"/>

SOURCE MEDRAD Interventional
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very pleased to ... as its new Chief Executive Officer.  Mark was promoted from ... has overseen the company,s four facilities in Massachusetts ... Mr. King joined Tegra Medical in 2012 with 20+ years ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Incorporated,(Nasdaq: VICL ) today announced the receipt ... from AnGes MG, Inc., under a previously announced,collaborative ... Phase 3 metastatic melanoma trial. Through a series ... $15.3 million to date,of the $22.6 million total ...
... vaccine induced neutralizing antibodies against widely divergent ... Baxter International,Inc. (NYSE: BAX ) announced publication ... England Journal of Medicine (NEJM) of data demonstrating ... I/II trial,endpoints for safety and immunogenicity (generating a ...
Cached Medicine Technology:Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 2Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 3Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 2The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 3The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 4The New England Journal of Medicine Publishes Study Investigating the Safety and Efficacy of Baxter's Cell-Based Pandemic, Avian Flu Vaccine 5
(Date:4/18/2014)... could lead to potential new treatments for breaking the ... , Fibrosis, or scarring, is a hallmark of the ... can lead to serious organ damage and, in some ... centers on findings made by Swati Bhattacharyya, PhD, research ... a specific protein plays in promoting fibrosis. , ...
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
(Date:4/17/2014)... synthetic biology team has created a new technology ... that could travel the body and selectively target ... cell-based, biological devices that monitor and modify human ... biology. However, no existing technology enabled bioengineers to ... state and respond in a customized fashion. , ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
... RANCHO CORDOVA, Calif., March 9 ... program announced it helped the 500,000th child since ... almost $100 million in free eyecare and eyewear ... http://www.newscom.com/cgi-bin/prnh/20090309/SF80394 )Sight for Students started as ...
... Usage Trends and Growing Uninsured Population Raise Concerns ... Report from HealthLeaders-InterStudy NASHVILLE, Tenn., March 9 ... market intelligence, reports that through the first three ... health insurers saw on average a 25 percent ...
... with therapy if subjects are willing and motivatedANN ARBOR, Mich., ... raised in an upper-middle class suburb, she felt a deep ... basement where she rode her Big Wheel at age 3 ... 8.As years went by, the home,s empty spaces disappeared, replaced ...
... Nu Skin Presents Findings at Asian Societies of Cosmetic ... a newly identified internal free radical generator, age-related NOX ... (NYSE: NUS ) links the enzyme to ... The research was presented at the 9th Scientific Conference ...
... Philanthropist and Renowned Chef Art Smith Creates Oat-Inspired Menu ... In Times Square today, Quaker announces ... purpose movement powered by Quaker and the human energy ... lives every day with the wholesome goodness of whole-grain ...
... wireless customer relationship management (CRM) experts, today ... and compliance software solution. iComply helps companies ... email for improved compliance with government regulations, ... The software is offered with a Lotus ...
Cached Medicine News:Health News:VSP's Sight for Students Program Helps 500,000th Child 2Health News:VSP's Sight for Students Program Helps 500,000th Child 3Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 2Health News:Florida Emergency Room Costs Increased 25 Percent in the Last Year and May Lead to More Opportunity for Pharma Industry 3Health News:Compulsive Hoarding Poses Safety and Psychological Risks 2Health News:Compulsive Hoarding Poses Safety and Psychological Risks 3Health News:Study Links Internal Source of Aging and Skin Damage 2Health News:Study Links Internal Source of Aging and Skin Damage 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 2Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 3Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 4Health News:Quaker Oats and Share Our Strength Announce New Movement to Fight Childhood Hunger 5Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 2Health News:iEnterprises Launches iComply, Lotus Notes Email Archiving and Compliance Software 3
... Peg electrodes typically are positioned ... enable epidural recording of brain ... and are furnished in several ... thicknesses. A 4.6 mm twist ...
... cortical strip electrodes are extra thin ... through a burr hole. The narrow ... enables quick and secure attachment to ... Integra Epilepsy electrode designs, they are ...
... John R. Gates and Mary E. Dunn ... are designed for reliability, safety and ease ... electrodes, platinum contacts are mounted flush with ... have larger exposures. Strip and depth electrodes ...
Integra Epilepsy grid electrodes are thin and flexible for easier placement and to conform to the curvature of the cortical surface. Lead tunneling is done using a 14-gauge tunneling needle (ET-2)....
Medicine Products: